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ABSTRACT 
Breast cancer is one of the most common causes of cancer related death in women around the 
globe. The process of tumor invasion and subsequent metastasis represents the most lethal aspect 
of breast cancer like any other cancer and is responsible for the majority of deaths among cancer 
patients. Our objective was to identify specific genes involved in such phenomenon or any other 
mechanism/networks in breast cancer. We analyzed microarray data of breast cancer tissues 
samples and compared with array of normal breast epithelium to obtain a list of 255 genes that 
are differentially expressed in breast cancer patients. Out of 255, 153 genes were reported to be 
down-regulated and 102 genes were up-regulated in breast cancer. From this differentially 
expressed genes list, we choose two genes, EGR1 & LAMB1 for experimental validation in cell 
lines, because their de-regulation might be contributing factor of breast cancer by affecting 
pathways/processes in the body. The expressions of these two genes were validated by qRT-PCR 
in MDA-MB-231 breast cancer cell lines, followed by elucidating their association in various 
biological networks. 
 
Key words: Microarray, clustering, breast cancer, qRT-PCR, cancer cell lines 
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1. INTRODUCTION 
The term cancer was coined by Hippocrates in the fifth century BC, which means “crab” in 
Latin. It describes a condition in which cells divide and spread unrestrained throughout the 
body, eventually choking off life.  The disease has existed for at least several thousand years 
and its prevalence has been steadily increasing. It is seen that cancer strikes older people 
more frequently than younger people and more cancer cases are being seen in older age. The 
increase in average lifespan-due mainly to the availability of vaccines and antibiotics that 
have lowered death rates from infectious diseases-resulting in more and more people living 
long enough to develop cancer.  
Breast cancer is one of the most common causes of cancer related death in women 
over the world. Globally, breast cancer accounts for an estimated 1.4 million cases each year, 
with more than half of the 400,000 breast cancer deaths occurring in low and middle income 
countries. Although therapeutic approaches, such as surgery, chemotherapy and radiation 
therapy, have reduced cancer specific mortality, there still are many therapeutic failures 
which result in cancer recurrence, metastasis and death. 
Gender and age are important risk factors for breast cancer; rates are about 100 times 
higher in women than in man, and about 80% of all cases are diagnosed in women over 50 
years of age. Roughly 10% of all breast cancers are linked to a family history of a disease, 
associated mainly with inherited mutation in the BRCA1 or BRCA2 genes. Those who have 
had extensive exposure to ionizing radiation in the chest area incur an increased risk for 
breast cancer, and reproductive and hormonal history play an important role as well. It is also 
seen that menstruation at an early age or go through menopause at a late age are at slightly 
increased risk, as are women who have had no children or who had their 1st child after age 30. 
From a wide range of study it was seen those who used oral contraceptives; exhibit a slight 
elevation in breast cancer risk. Use of alcohol, obesity and lack of physical exercise are 
additional risk factors. Some reports have suggested that environmental pollution involving 
pesticides that mimic the action of estrogens can promote the development of breast cancer, 
although current evidence does not show a consistent link.  
The 1st symptom of breast cancer is usually a lump detected during breast self-
examination. Unexplained breast swelling, thickening, skin irritation or dimpling, tenderness, 
nipple pain and discharge other than breast milk are other possible signs. Mammography is 
capable of detecting small breast cancers before they can be felt by a woman or by her 
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physician. It is therefore currently being recommended that women over age 40 begin regular 
mammography to screen for breast cancer. When physical examination or mammography 
indicates the presence of an abnormal mass, a biopsy is done to determine whether cancer is 
present. 
Breast cancer has been attributed to diverse causes but the real mechanism underlying 
cancer development remains obscure. Elucidation of such mechanism requires thorough 
knowledge of the genes involved and their regulation strategies. With the invention of DNA 
microarray technology, it is now possible to look globally at gene expression across the 
genome. By studying gene expression profile we can know the interactions between genes 
and how this ultimately impacts on the pathology of diseases. (Fey M et. al. 2002). Such 
DNA microarray analysis has been used to investigate the underlying biology of many cancer 
types, including breast cancer (Duffy et .al., 2005).This type of analysis can be applied to 
every aspect of the disease including initiation, progression, invasion and drug resistance with 
the aim of elucidating the underlying molecular mechanisms involved (Bertouchi et.al.,2001). 
There have been many studies using breast cancer cell lines (Zajchowski and Perou et.al , 
2000) which have used DNA microarrays in an attempt to develop molecular portraits, 
classifications and prognostic signatures of breast cancer (Brennan et.al., 2005). 
The main aim of our work is to find a set of key genes which have significant roles in 
breast cancer like tumor suppression and inhibiting metastasis and also to find out how they 
are regulating other genes or pathways. If we somehow regulate their expression, there might 
be a cure or reduction in tumor invasiveness. To do that, microarray analysis of tumor versus 
control sample was done using Genespring, followed by gene ontology study using String 
and Genomatix software. These analysis lead to the selection of two genes for further study 
based upon their regulation and association with cancer. Expressions of these two genes were 
confirmed in MDA-MB-231 cell line which is a breast cancer cell line, taking β-actin (a 
housekeeping gene) as reference gene through qRT-PCR. This study can lead to possible 
discovery of genes which play a key role in tumor invasiveness. 
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2. REVIEW OF LITERATURE 
Cancer is characterized by the abnormal growth and proliferation of cells in an uncontrolled 
manner .Such cells can arise in a variety of tissues and organs and each of these sites contains 
different cell types.  
Benign and malignant tumours 
No matter where a cancer arises and regardless of the cell type involved, the diseased can be 
defined by a combination of 2 properties i.e. 
• The ability of the cells to proliferate in an uncontrolled fashion. 
• Their ability to spread throughout the body.     
Tumours types 
On the basis of differences in the growth patterns of tumours are subdivided in to 2 
fundamentally different categories. One group consists of benign tumors, which grow in a 
confined local area. Another is malignant tumors that can invade surrounding tissues, enter 
the bloodstream, and spread to distant parts of the body by the process called metastasis. The 
cells of a malignant tumour often spread to other parts of the body. Malignant tumours 
therefore tend to be more hazardous than benign ones. Benign tumours on the other hand 
arise in surgically inaccessible locations, such as the brain, making them hazardous and 
potentially life threatening.  
                    Differences in growth rate and state of differentiation are also common 
between benign and malignant tumours. Benign tumours generally grow rather slowly and 
are composed of well differentiated cells, meaning that the cells bear a close structural and 
functional resemblance to the normal cells of the tissue in which the tumour has arisen. 
Malignant tumours, on the other hand ,often grow more rapidly and their state of 
differentiation is variable, ranging from relatively well differentiated tumours to tumours 
whose cells are so poorly differentiated that they bear almost no resemblance to the original 
cells from which they were derived. Therefore the malignant cell pool constitutes a 
heterogeneous population of cells with varying degrees of differentiation, from stem cell like 
to fully differentiated ones. 
Nomenclature of tumors according to site of origin  
Because tumours can arise from a variety of cell types located in different tissues and organs, 
some basic conventions have been established to facilitate the naming of cancers. Depending 
on their site of origin, cancers are grouped into 3 main categories i.e. 
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(1) Carcinomas are cancers that arise from the epithelial cells that form covering layers over 
external and internal body surfaces. Carcinomas are by far the most common type of 
malignant tumour, accounting for roughly 90% of all human cancers. 
(2) Sarcomas are cancers that originate in supporting tissues such as bone, cartilage, blood 
vessels, fat, fibrous tissue and muscle. They are the rarest group of human cancers, 
accounting for about 1% of the total. 
(3) The remaining cancers are lymphomas and leukaemia, which arise from cell of 
lymphatic and blood origin. The term lymphoma refers to tumours of lymphocytes that 
grow mainly as solid masses of tissue, whereas leukaemia are cancers in which malignant 
blood cells proliferate mainly in the bloodstream(Kleinsmith et.al.,2009) .  
 
Table 1: Nomenclature of tumors according to their origin (Kleinsmith et.al. 2009) 
 
Prefix Cell type Benign tumor Malignant tumor 
Epithelium 
Adeno Gland Adenoma Adenocarcinoma 
Basal cell Basal cell Basal cell adenoma Basal cell carcinoma 
 
Squamous cell Squamous cell 
 
Karatoacanthoma 
 
Squamous cell carcinoma 
Melano Pigmented cell Mole Melanoma 
Supporting Tissue 
Chondro Cartilage Chondroma Chondrosarcoma 
Fibro Fibroblast Fibroma Fibrosarcoma 
Hamangio Blood vessels Hemangioma Hemangiosarcoma 
Leiomyo Smooth muscle Leiomyoma Leiomyosarcoma 
Lipo Fat Lipoma Liposarcoma 
Meningio Meninges  Meningioma Meningiosarcoma 
Myo Muscle Myoma Myosarcoma 
Osteo Bone Osteoma Osteosarcoma 
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Rhabdomyo Striated muscle Rhabdomyoma Rhabdomyosarcoma 
Blood and lymph 
Lympho Lymphocyte  Lymphoma 
Erythro Erythrocyte  Erythrocytic leukemia 
Myelo Bone marrow  Myeloma 
     
Breast cancer has been attributed to diverse causes but the real mechanism underlying 
cancer development remains obscure. The cause lies underneath, may be due to activation or 
inhibition of different regulatory pathways or it may be due to up or down regulation of some 
genes. To solve the mystery an effective technology is being used known as DNA 
microarray.  
                DNA microarray analysis is a powerful tool in the armory of the molecular 
biologist, as it allows examination of thousands of genes in parallel (Schena et.al., 1998). 
With the invention of DNA microarray technology, it is now possible to analyze gene 
expression across the genome simultaneously, under identical conditions and to find patterns 
of expression. Patterns of gene expression should lead to a better understanding of the 
complex interactions between genes and how this ultimately impacts on the pathology of 
disease (Fey M et.al, 2002).  
DNA microarray analysis has been used to investigate the underlying biology of many 
cancer types, including breast cancer (Brennan, et.al.2005). This type of analysis can be 
applied to every aspect of the disease including initiation, progression, invasion and drug 
resistance with the aim of elucidating the underlying molecular mechanisms involved 
(Bertouchi et.al. 2001). There are many published studies using breast cancer cell lines 
(Zajchowski et.al., 2001)and breast tumor tissue (Perou et.al.,2000) which have used DNA 
microarrays in an attempt to develop molecular portraits, classifications and prognostic 
signatures of breast cancer (Brennan, et.al.2005). An example of the potential for DNA 
microarrays in the clinical management of patients with cancer is the 70-gene prognostic 
breast cancer signature (Van’t Veer et.al. 2002), which is now undergoing evaluation in 
clinical trials. Using of this technology for the characterization of a series of invasive 
subclones with different levels of invasion in primary human breast cancer cell line, Hs578T, 
is being established. 
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        Different tools and softwares are used to analyze the microarray data and set up 
biological networks. It includes: 
• Genespring: It is a commercially available software used for microarray analysis. 
• String: It is a database to set up interaction between different genes. 
• Genomatix: It is a commercially available software for establishing biological 
network and pathway interaction study.  
• Bioconductor: It is an open source software for analyzing microarray data. 
• TM4: It is a free software for microarray analysis and it has mainly 4 applications 
i.e. Spotfinder, Microarray Data Manager (MADAM),Microarray Data Analysis 
System (MIDAS), and Multiexperiment Viewer (MeV). 
• Spotfire: It is commercially available software for microarray data analysis. 
• R: It is free software for statistical computing and graphics.  
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OBJECTIVES 
 
Objective 1 
 
• To check the expression profile analysis of genes associated with breast cancer using 
microarray data. 
 
Objective 2 
 
• Selection of a set of key genes associated in breast cancer. 
 
Objective 3 
 
• Experimental validation of selected genes.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
  
Materials and Methods 
 
 
 
 
 
8 
 
3. MATERIALS & METHODS 
Gene Expression data 
First we have to check mRNA expression between normal vs. diseased. To see that following 
approach is taken. 
• To see mRNA expression between normal vs. diseased DNA microarray data is used 
from the GEO database.  
• The DNA microarray data are stored in GEO database. So from there only we can 
retrieve this type of data. 
3.1 Retrieval of gene expression data 
• The gene expression data was retrieved by using of GEO database. 
GEO database 
GEO (http://www.ncbi.nlm.nih.gov/geo/) is a data repository and retrieval system for any 
high throughput gene expression. It contains data from different microarray experiments as 
well as non-array based technologies such as SAGE and mass spectrometry peptide profiling.  
GEO segregates data in to 3 principle components, platform, sample and series. A platform is 
essentially a list of probes that define what set of molecules may be detected. A sample is a 
set of molecules that are being probed and references a single platform used to generate its 
molecular abundance data. A series organizes samples in to meaningful datasets which make 
up an experiment (Mallick et.al. 2012). 
Basic retrieval of GEO data    
There are 2 ways by which the GEO data may be retrieved 
• GEO data may be retrieved by querying GDS (GEO datasets), gene profiles and GEO 
accession numbers. 
• GEO data can be accessed directly on the web by browsing through datasets or GEO 
accessions options available with respect to individual platform, sample and series. 
Related records are intra-linked on the GEO sites such that one may conveniently 
navigate to the associated platform, , series, sample and  GEO dataset records. 
Analysis through GEO data base 
• Go to main page of GEO data base. 
• Type mRNA expression in breast cancer AND homo sapiens in data setsoption. 
• Then click on GO.  
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      Figure 1: Retrieval of microarray data from the GEO database for the experiment 
 
• Then results appear which contain the list of microarray experiments. 
• From that each GSE is checked for expression profile analysis having platform [HG-
U133A] Affymetrix Human Genome U133A Array and the expression is without 
induce of any drug. 
• From that GSE9574 is taken for analysis. 
• From that 3 controls (normal) and 3 tests (disease) samples were taken. 
• For control GSM242005 
       GSM242006 
       GSM242007 is taken for analysis. 
•  For test      GSM242020 
        GSM242021 
        GSM242022 is taken for analysis. 
• It was taken in triplicate because to minimize the error. 
• From that a raw file is down loaded, it was unzip and for further analysis it is 
uploaded in GeneSpring software. 
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• To see which genes are associated with the expression of mRNA and their regulation 
in breast cancer software is used known as GeneSpring. 
3.2 Analysis of gene expression data 
• Expression data is analyzed by using Genespring software. 
GeneSpring software 
 
GeneSpring is software which provides statistical tools for visualization and data analysis. It 
helps to investigate and understanding of Transcriptomic, Metabolomics, Proteomics and 
NGS data within a biological context. It also helps in expression analysis. This software is a 
key component of systems biology research involves producing heterogeneous data that 
measure various biological entities and events such as variation in DNA structure, expression 
of microRNA and mRNA exon splicing, proteins and metabolites, which helps to understand 
underlying mechanism of diseases.  
It also allows researchers to analyse, compare different signalling pathway.  
Other applications of GeneSpring include: 
• Gene expression analysis of microarray platforms like Affymetrix, Agilent and      
Illumina. 
• Analysis of Real-time PCR data. 
• GEO datasets. 
 
    Figure 2: Clustering analysis of normal and diseased samples 
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Data analysis using GeneSpring 
For mRNA expression analysis: 
Procedure 
• The raw data files from GEO database were downloaded as a zip file. 
• Then the files were unzipped, extracted and renamed according to the convenience. 
• First we have to select a new project under which many platforms will come from that 
we have to select our desired platform type. 
• Then we have to give the name of the project. 
• Then we have to set a new experiment by setting experiment name and experiment 
type. 
• Then guided work flow is chosen as work flow type. 
• Then data is loaded and the desired technology is selected i.e. Affymetrix Gene Chip-
HG-U113A. 
• Then files were chosen as 3 replicates i.e. Control and Test files. 
• Then by normalizing the noise signal the intensity map can be seen. 
• Then Experimental setup was done by following methods. 
 First experimental grouping is done by add parameters to Average.    
 Then Average over replicates in condition is chosen in case of Create 
Interpretation.         
• Then quality control is done by following methods. 
 First we have to set Filter Probe sets by errors. 
 Then the coefficient of variation is chosen < 50%. 
 Then we have to choose Output views of filter. 
 Then the entity list is saved. 
• Then Analysis was done by following method 
 First Statistical Analysis is chosen. 
 After that Entity list is Filtered on error <50. 
 Then the Interpretation is chosen Average. 
 Condition 1 and Condition 2 for Select test. 
 T-test is unpaired chosen for 2 sets of data. If more than 2 sets be present then 
Anova should be chosen. 
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 Then the p- value computation is chosen Asymptomatic. 
 Then the Number of permutation should be 100. 
 Then Multiple testing correction is chosen Benjamin Hochberg FDR. 
 Then in Results cut-off should be chosen ≤ 0.05 which is present by default. 
 Then the entity list is saved. 
• Then the Fold Change is chosen and done by following these Input parameters and 
pairing options. 
 The Fold change results cut-off should be >=2.0. 
• Then Clustering was done by following methods: 
 First Input parameters are taken. 
• Then in Entity list, Fold change >=2.0 is chosen. 
• Then the Interpretation is chosen all samples. 
• The Cluster algorithm is chosen Hierarchical. 
• The Cluster is done on Conditions 
• Then the Distance metric is chosen Pearson uncentered. 
• The Linkage rule is chosen Average. 
• Then Result file is saved. 
• After that Result interpretation was done by following method 
• Then GO analysis by choosing output views. 
• Export of  Fold change data was done by adapting the method: 
 First we have to Export the entity list. 
 Then we have to normalize the signal values. 
 Then - Gene symbol and Entrez gene is selected in selected items. 
 Then Interpretation of All samples is done. 
• Then it is Saved as- Tab separated file (.txt) 
 
• Then we have to see how the control varies from test sample. 
• To see how the control varies from test sample clustering is done by using Cluster3 
and java treeview software is used. 
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3.3.Cluster3 and java treeview software 
 
Cluster3 and java treeview are the softwares which help in analyzing data from the 
GeneSpring.  
Loading, filtering, and adjusting data 
We can be load data into Cluster by choosing Load data file clicking the File menu. Then a 
number of options appear which helps in adjusting and filtering the loaded data. These can be 
done by Filter Data and Adjust Data tabs. 
 
Figure 03: Analysis of data using cluster3 software 
Loading Data 
The first step for Cluster is to import data. The data can be imported from the Microsoft 
Excel file. Cluster only reads tab-delimited text files so we have to first convert it in to .txt 
format to upload. For e.g. a demo data file is uploaded for checking the expression of the 
normal and diseased samples. 
Filtering Data 
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With the help of Filter Data tab one can remove genes that do not have desired properties 
which we need for our dataset.  
 
Clustering techniques 
The Cluster program provides several clustering algorithms. There are 4 clustering methods 
are available i.e. Hierarchical ,K-means, SOM(Self-Organizing Maps ) and PCA(Principal 
Component Analysis ).We mainly use Hierarchical clustering methods for our analysis. It 
organizes genes in a tree structure, based on their similarity.  
Java treeview 
Java treeview is software which allows analyzing the results of Cluster. It reads in .cdt, .gtr, 
.atr, .kgg, or .kag file formats which are being produced by Cluster. 
• After that we have to see how these 2 genes regulate expression by associating with 
their neighboring genes. 
• To see that another database is used known as string. (Search Tool for the Retrieval of 
Interacting Genes database). 
3.4. String database 
Proteins can form a variety of functional connections witheach other, including stable 
complexes, metabolic pathways and a bewildering array of direct and indirect regulatory 
interaction. Otherwise these can be known as networks and the size and complex organization 
of these networks present a unique opportunity to view a given genome as something more 
than just a static collection of distinct genetic functions. Indeed, the ‘network view’ on a 
genome is increasingly being taken in many areas of applied biology: protein networks are 
used to increase the statistical power in human genetics (Pattin, et.al., 2009; Pujol et.al., 
2010) to close gaps in metabolic enzyme knowledge and to predict phenotypes and gene 
functions (Lage. et al, 2007; Wang et.al., 2010) to name just a few examples. Protein– protein 
association information is highly useful for the users and it should be easily available in web 
and should be easily accessible for the users. The Search Tool for the Retrieval of Interacting 
Genes (STRING) database resource aims to provide this service, by acting as a ‘one-stop 
shop’ for all information on functional links between proteins. STRING is the only site which 
covers the interaction map of hundreds more than 1100 organisms ranging from single cell 
organism to humans.  
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Analysis using string database 
 
 
Figure 04: Analysis of genes using string database 
 
• Here multiple names are selected. 
• homo sapiens should be selected in organism name. 
• After that gene list should be added in list of name box. 
• Then GO option is chosen. 
• Then it will show the gene list which are uploaded and their function. 
• Then continue option is chosen for further analysis. 
• By changing different parameter analysis is done. 
• Then update parameters for the interaction analysis. 
 
• Again it is analyzed in software named as Genomatrix. 
• It is also interaction based software. 
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• Then the expression data obtained from the gene spring was further validated by wet 
lab analysis by selecting the 2 genes i.e.EGR1 and LAMB1 with a normal gene 
named as β actin.   
 
3.5 Experimental Validation 
3.5.1 Cell culture 
• MDA- MB-231 breast cancer cell lines are cultured for isolation of RNA. 
MDA MB 231 cell line 
The MDA-MB-436 breast cancer cell line was first derived from pleural fluid obtained from 
a 43-year-old breast cancer patient in 1976. It is pleomorphic and reacts intensely with anti 
tubulin antibody. The MDA-MB-231 cell line is also able to grow on agarose, an indicator of 
transformation and tumorigenicity, and displays a relatively high colony forming efficiency. 
In vivo, the MDA-MB-231 cells form mammary fat pad tumors in nude mice.  
 
Figure 05. MDA-MB-231 Cell Line. Left: RFP Fluorescence; Right: Phase Contrast. 
• Before culturing these cell lines are maintained in 20° c in carbon dioxide incubator. 
• Media used for these cell cultures is DMEM. 
• Freeze Medium is 70% DMEM, 20% FBS, 10% DMSO.  
Methods of cell culture 
 Human breast carcinoma cell line, MDA MB 231 was obtained from National Centre For 
Cell Science (NCCS), Pune, India. The medium used for culturing the cell is MEM 
(Invitrogen; MEM with NEAA (non essential amino acids) and L-Glutamine) with 10% FBS 
17 
 
(Fetal bovine serum from HIMEDIA) and 1% antibiotic solution (Penstrep solution from 
HIMEDIA). The culture flask containing the cell line is kept in the CO2 incubator with the 
level of CO2 maintained at 5%. With the utilization of medium the color of the medium 
changes from red to orange and then pale yellow because of change in pH of the medium.  
The steps for cell culture was as followed: 
 
 
1. The cells were harvested first. 
• Cells were grown in suspension i.e. 1 x 107 cells. The number of cells was 
determined. The appropriate number of cells was pelleted by centrifuging for 5 min at 
300 x g in a centrifuge tube. Carefully removed all supernatant by aspiration 
completely from the cell culture medium. 
• To trypsinize and collect cells: The number of cells was determined. The medium was 
aspirated, and the cells were washed with PBS. Then the PBS was aspirated, and 0.1–
0.25% trypsin in PBS was added. After the cells detach from the flask, medium 
(containing serum to inactivate the trypsin)was added , the cells were transferred  to 
an RNase-free glass or polypropylene centrifuge tube and centrifuged at 300 x g for 5 
min. The supernatant was aspirated completely, and proceeded to step 2.  
2. The cells was disrupted by adding Buffer RLT: 
• For pelleted cells, loosen the cell pellet thoroughly by flicking the tube. 350 μl Buffer 
RLT was added. Vortexed or pipetted to mix, and ensured that no cell clumps were 
visible and proceeded to step 3. 
3. The lysate was homogenize for 30 s using a rotor–stator homogenizer and proceeded 
to step 4. 
4.  1 volume of 70% ethanol was added to the homogenized lysate, and mixed well by 
pipetting.  Did not centrifuge.        
5. 700 μl of each sample was transferred from step 4, including any precipitate to each 
RNeasy spin column on the vacuum manifold. 
6. The vacuum was switched on and was applied until transfer was complete. Then 
switched off the vacuum and ventilated the vacuum manifold. 
7. 700 μl Buffer RW1was added to each RNeasy spin column. 
8. The vacuum was switched on and was applied until transfer was complete. Then 
switched off the vacuum and ventilated the vacuum manifold. 
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9. 500 μl Buffer RPE was added to each RNeasy spin column. 
10. The vacuum was switched on and was applied until transfer was complete. Then 
switched off the vacuum and ventilated the vacuum manifold. 
11. 500 μl Buffer RPE was added to each RNeasy spin column. 
12. The vacuum was switched on and was applied until transfer was complete. Then 
switched off the vacuum and ventilated the vacuum manifold. 
13.  The RNeasy spin columns was removed from the vacuum manifold, and was placed 
each in a 2 ml collection tube. The lids were closed gently, and centrifuged at full 
speed for 1 min. 
14.  Each RNeasy spin column was placed in a new 1.5 ml collection tube. 30–50 μl 
RNase free water was added directly to each spin column membrane. The lids were 
closed gently, and centrifuged for 1 min at 8000 x g (10,000 rpm) to elute the RNA. 
15.  If the expected RNA yield is >30 μg, then step 15 was repeated using another 30–50 
μl RNase free water or using the eluate from step 14 (if high RNA concentration is 
required). The collection tubes were reused from step 14. 
 Note: If using the eluate from step 14, the RNA yield will be 15–30% less than that obtained 
using a second volume of RNase-free water, but the final RNA concentration will be higher. 
 
3.5.2. RNA ISOLATION  
The kit used for RNA isolation was from QIAGEN.  
1. A maximum of 1×107 cells was harvested, as a cell pellet or by direct lysis of/in 
vessel. The appropriate volume of Buffer RLT was added. 
2. 1 volume of 70% ethanol was added to the lysates and mixed well by pipetting. Did 
not centrifuge. Proceeded immediately to step 3. 
3. Up to 700 µl of the sample was transferred, including any precipitation, to an RNeasy 
Mini spin column placed in a 2ml collection tube (supplied). The lid was closed and 
centrifuged for 15s at ≥8000×g.  The flow –through was discarded. 
4. 700 µl Buffer RW1 was added to the RNeasy spin column. The lid was closed and 
centrifuged for 15s at 8000×g.  The flow –through was discarded. 
5. 500 µl Buffer RPE was added to the RNeasy spin column. The lid was closed and 
centrifuged for 15s at ≥8000×g.  The flow –through was discarded. 
6. 500 µl Buffer RPE was added to the RNeasy spin column. The lid was closed and 
centrifuge for 2 min at ≥8000×g.   
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7. The RNeasy spin column was placed in the new 1.5 ml collection tube. 30-50 µl 
RNase- free water was added directly to the spin column membrane. The lid was 
closed and centrifuged for 1min at ≥8000×g to elute the RNA. 
8. If the expected RNA yield is >30 µg, then step 7 was repeated using another 30-50µl 
of RNase- free water, or using the eluate from step-7.  The collection tubes were 
reused from step-7.  
9. The purity and yield of RNA yield was measured by Eppendorf NanoDrop. It is a 
cuvette free spectrophotometer which eliminates the need for other sample 
containment devices and allows for clean up in seconds. It measures 1 µl samples 
with high accuracy and reproducibility. The full spectrum (220nm-750nm) 
spectrophotometer utilizes a patented sample retention technology that employs 
surface tension alone to hold the sample in place. A 1 µl sample is pipetted onto the 
end of a fiber optic cable (the receiving fiber). A second fiber optic cable (the source 
fiber) is then brought into contact with the liquid sample causing the liquid to bridge 
the gap between the fiber optic ends. The gap is controlled to both 1mm and 0.2 mm 
paths. A pulsed xenon flash lamp provides the light source and a spectrometer 
utilizing a linear CCD array is used to analyze the light after passing through the 
sample. The instrument is controlled by PC based software, and the data is logged in 
an archive file on the PC. 
3.5.3. cDNA Synthesis 
cDNA synthesis was carried out using SuperScript First-Strand Synthesis System for RT-
PCR by Invitrogen using oligo dT primers. 
The steps in cDNA synthesis: 
1. Each of the components were mixed and briefly centrifuged before use. 
2. For each reaction, the following in a sterile 0.2 or 0.5ml tube was combined. 
 
 
 
 
 
20 
 
 
 
 
 
 
 
 
1. The RNA/primer mixture at 65·c for 5 minutes was incubated, and then placed 
on ice for at least 1 minute.  
2. In a separation tube, the following 2X reaction was prepared by adding each 
component in the indicated order. 
 
Components 1RXn 10 RXns 
10X RT buffer 2 µl 20 µl 
25mM Mgcl2 4 µl 40 µl 
0.1M DTT 2 µl 20 µl 
RNase out TM (400/ µl) 1 µl 10 µl 
 
1. 9µl of the 2X reaction mixture was added to each RNA/primer mixture from 
step3, mixed gently and collected by briefly centrifuge. 
2. It was incubate at 42°c for 2 minutes. 
3.  1µl of super script TM II RT was added to each tube. 
4. It was incubate at 42°c for 50 minutes. 
5. The reaction was terminated at 70·c for 15 minutes. Chilled on ice. 
6. The reaction was collected by brief centrifugation. 1µl of RNase H was added 
to each tube and incubated for 20minutes at 37·c. The reaction was used for 
PCR immediately. 
3.5.4. Real time PCR 
Real time PCR is a method that allows exponential amplification of DNA sequences and 
simultaneously quantifies it. This system is based on the detection and quantitation of a 
Components 
 
Amount 
RNA 
 
4 µl 
10 mM dNTP mix 
 
1 µl 
Primer (0.5µg/µl oligo (dT)12-18 or 2µM gene 
specific primer) 
1µl 
DEPC treated water  4µl 
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fluorescent probes. Probes which are used in qRT-PCR are taqman probes, molecular beacon 
, SYBR® Green, displacing probes, light up probes etc. For present study we used SYBR® 
Green probe which is a frequently used fluorescent DNA binding probe and relies on the 
sequence specific detection dye. The genes which are taken for the experiment, are of two 
types test genes and reference genes. Reference genes are used to check for the expression of 
test genes i.e. how much fold they have increased or decreased with respect to normal 
expression. Reference genes should have following feature: the standard gene should have 
the same copy number in all cells, it should be expressed in all cells, a medium copy number 
is advantageous since the correction should be more accurate. For this experiment the test 
genes were ABCA8 and SMC4 and reference gene used is beta-actin. Beta actin is a house 
keeping gene also called as constitutive genes which are required for the maintenance of 
fundamental cellular function, and are expressed in all cells of an organism under normal and 
patho-physiological conditions. The total reaction volume could either be 5µl or 10µl. We 
prepared a total reaction volume of 10µl. 
Calculation: 
We took 3 genes, therefore, 
                   3 genes x 3 replicates = 9 x 10 = 90µl 
                                                                     =100µl (in case of pipetting error do addional  
                                                                                  10 µl is taken) 
i) SYBR ® Green master mix:- 
The stock solution is 2X concentration and working solution of 1 X concentration is 
prepared. 
                            2X x  (? µl) = 1X x 100µl 
Ö      (? µl) = 1X x 100µl / 2X 
             = 50µl 
SYBR ® Green master mix= 50µl 
ii) cDNA: 
                  cDNA =  cDNA stock : distilled water 
                                                     1 : 20 
cDNA=3µl 
Distilled water = 57µl 
Total= 3+57 µl=60µl 
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For each reaction we require 4µl of cDNA 
Therefore, for 10 reaction= 4x10= 40µl 
From the above made 60 µl we took 40µl 
iii) Primer:- The stock solution contains 10µM, we require 500nM for each reaction 
                      10 µM x  (? µl) = 500x1000µMx100 
Ö      (? µl) = 500x1000µMx100 /  10 µM 
Ö                = 5µl 
For forward and reverse primer 5x2=10µl 
SYBR ® Green master mix + cDNA + Primer= (50 +40+10) µl= 100 µl 
                                                100µl 
 
 
Gene 1         Gene 2            Gene 3  
                             For each gene 3 replicates is taken 
• For Real time PCR analysis mainly 2 types of primers are used. 
• There are 3 genes taken. One is EGR1 gene, another is LAMB1 gene and another is 
normal gene for checking the expression. 
• The primer sequence are ordered from Sigma and sequence for each gene are: 
Table 2: Table showing the sequence of the forward and backward primers 
 
PRIMER  TYPE SEQUENCE 
EGR1 Forward  GGTCAGTGGCCTAGTGAGC 
Reverse  GTGCCGCTGAGTAAATGGGA 
LAMB1 Forward AGGAACCCGAGTTCAGCTAC 
Reverse CACGTCGAGGTCACCGAAAG 
β actin Forward CATGTACGTTGCTATCCAGGC 
Reverse CTCCTTAATGTCACGCACGAT 
 
• Real-time PCR was carried out in Eppendorf  Masterplex Real Time PCR.  
1. The primer concentrations were normalized and gene-specific forward and reverse primer  
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pair was mixed. Each primer (forward or reverse) concentration in the mixture was 3.5 μl. 
2. The experiment was set up and the following PCR program was made on. A copy of the  
setup file was saved and all PCR cycles were deleted. The threshold frequency taken was  
33%. The cycle temperatures taken were as follows: 
Table 3: Cycle temperature and time for qRT-PCR 
STAGE TEMPERATURE (°C) TIME CYCLE 
Stage 1 95 20 sec 1 
 
Stage 2 
95 
55 
68 
15 sec 
15 sec 
20 sec 
 
40 
 
Stage 3 
95 
60 
95 
15 sec 
15 sec 
15 sec 
 
1 
 
 
 
   
           
             Figure 06. Cycle temperature and time for qRT-PCR 
 
  
 
Results and Discussion 
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4. RESULTS & DISCUSSIONS 
In study of breast cancer cells, EGR1 and LAMB1 gene expression was up regulated 
compared with the normal cells. The observation was confirmed by doing experiment Insilco 
as well as in lab. Experiment was performed by RNA isolation from MDA Mb 231 breast 
cancer cells and its expression was checked by running real time PCR and agarose gel.β actin 
a house keeping gene that shows same expression in all kind of cells was visualized for its 
expression. When normal cell was compared with breast cancer cells EGR1 expression was 
down in normal cells while well bright band was observed in breast cancer cells suggesting it 
is up regulated in breast cancer and LAMB1 expression is up regulated. 
 
 
 
 
Figure 07: Intensity map of the control and test samples 
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Figure 08: Experimental grouping is done by add parameters to Average 
 
 
 
 
Figure 09: Filtering Probe sets by errors 
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Figure 10: T-test is unpaired chosen for 2 sets of data 
 
 
 
Figure 11: Fold change results by taking cut-off >=2.0. 
 
27 
 
 
 
Figure 12: Hierarchical clustering of output views. 
 
 
 
Figure 13: Hierarchical clustering by taking Interpretation all samples 
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• A list of 255 genes is generated by gene spring analysis that is differentially expressed 
in breast cancer patients. Out of 255, 153 genes were reported to be down-regulated 
and 102 genes were up-regulated in breast cancer. 
• These genes are further analyzed in Cluster 3 and java treeview software which 
generated a hierarchical clustering dendrogram as follows. 
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Cluter3 and java treeview result:- 
 
Figure 14: Clustering results of genes using java treeview software 
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 From the list of 255 genes which are obtained from using GeneSpring software were 
further analyzed by using different software and databases. 
 Genes which have fold change value >3 are taken for analysis from the list of 255 
genes. 
 It is done by searching in different data base and literature search. 
 From that 2 genes are selected for further analysis by seeing its regulation in different 
pathways. 
 These 2 genes are EGR1 (Early growth response 1) and LAMB1 (Laminin beta 1). 
 
• These 2 genes are analyzed in String database and Genomatrix software for to the 
interaction with the genes which play an important role in cancer invasiveness.  
 
String database result  
The interaction of EGR1 and LAMB1 gene with other genes are documented from string 
database. 
Association of EGR1 gene with other gene 
• TAKING EXPERIMENT-DATABASE-TEXTMINING PARAMETER ANALYSIS 
 
Figure 15: Interaction of EGR1 gene with other gene by taking Experiment-Database-Text 
mining parameter analysis 
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• TAKING TEXTMINING PARAMETER ONLY 
 
Figure 16: Interaction of EGR1 gene with other gene by taking Text mining parameter 
analysis 
• TAKING EXPERIMENT-TEXTMINING PARAMETER ONLY 
 
Figure 17: Interaction of EGR1 gene with other gene by taking Experiment-Text mining 
parameter analysis 
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• TAKING DATABASE-TEXTMINING PARAMETER ONLY 
 
 
Figure 18: Interaction of EGR1 gene with other gene by taking Database-Text mining 
parameter analysis 
Association of LAMB1 gene with other gene 
• TAKING EXPERIMENT-DATABASE-TEXTMINING PARAMETER ANALYSIS 
 
Figure 19: Interaction of LAMB1 gene with other gene by taking Experiment-Database-Text 
mining parameter analysis 
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• TAKING EXPERIMENT-DATABASE PARAMETER ONLY 
 
Figure 20: Interaction of LAMB1 gene with other gene by taking Experiment-Database 
parameter analysis 
 
• TAKING EXPERIMENT-TEXTMINING PARAMETER ONLY 
 
Figure 21: Interaction of LAMB1 gene with other gene by taking Experiment-Text mining 
parameter analysis 
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• TAKING DATABASE-TEXTMINING PARAMETER ONLY 
 
Figure 22: Interaction of LAMB1 gene with other gene by taking Database-Text mining 
parameter analysis 
• Then these 2 genes are also analyzed in genomatrix software to find association with 
its neighboring gene. 
Genomatrix results 
 
Figure 23:  Egr1showing Association with its neighboring gene 
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Figure 24: Lamb1 showing association with its neighboring gene 
• These are the symbols by which we can know which type of association occurring in 
between the genes.  
 
2 genes are associated by co-citation. 
 
2 genes are associated by expert-curation. 
 
Gene A activates Gene B. 
 
Gene A inhibits Gene B. 
 
Gene A modulates Gene B. 
 
Gene A alters the state of Gene B. 
 
If gene A has a known TF binding site matrix and gene B has a corresponding  
binding site in one of its promoters the arrow is filled black. For interactions 
that involve a complex, this arrow type is never used. To look for promoter 
bindings in this case, double-click on the edge and select the interaction of 
interest. 
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There is no promoter binding noted 
 
Real time PCR results 
Melting curve analysis of EGR1 and LAMB1 with β actin 
 
Figure  25:Showing the results of melting curve analysis of both EGR1 and LAMB1 using β 
actin as standard 
 
Melting curve analysis of only EGR1 gene with β actin 
 
Figure  26:Showing the results of melting curve analysis of  EGR1 gene using β actin as 
standard 
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In many tumor types, such as glioblastoma, lymphoma, and carcinomas of the lung and 
breast, EGR1 is low or absent, (Levin et.al, 1995; Huang et.al.1997; Calogero et.al, 2001 and 
Joslin et.al, 2007) indicating a tumor suppressive role. From the in silico data it was stated 
that Egr1 gene expression is down regulated in breast cancer. But from the melting curve 
analysis through RTPCR in breast cancer it was seen that it is up regulated. In other cancers 
like prostate cancer EGR1 has also been reported up regulated (Gregg et.al, 2011) .  
Melting curve analysis of only LAMB1 gene with β actin 
 
Figure  27:Showing the results of melting curve analysis of  LAMB1 gene using β actin as 
standard 
 
 
 
Figure 28: Relative expression of EGR1 AND LAMB1 with respect to control 
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It was observed that EGR1 down regulated  and LAMB1 was up expressed in breast cancer. 
So it may concurred that a coordinated endeavor between basic molecular biology functional 
genomics and proteomics and cell signaling may provide information on the relationship of 
this down and up regulation of genes . 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
    Conclusion 
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5. CONCLUSION 
We analyzed microarray data of breast cancer tissues samples and compared with array of 
normal breast epithelium to obtain a list of 255 genes that are differentially expressed in 
breast cancer patients. Out of 255, 153 genes were reported to be down-regulated and 102 
genes were up-regulated in breast cancer. From this differentially expressed gene list, we 
choose two genes, EGR1 & LAMB1 for experimental validation, because EGR1 is a 
transcription factor whereas LAMB1 is an extracellular matrix glycol protein. And they have 
significant role in tumor suppression and metastasis. Their de-regulation might be 
contributing factor of breast cancer by affecting various pathways/processes in the body. The 
expressions of these two genes were validated by qRT-PCR in MDA-MB-231 breast cancer 
cell lines, followed by elucidating their association in various biological networks. We found 
EGR1 to be down-regulated in breast cancer and this de-regulation possibly affect other 
downstream genes in pathways and networks related to breast cancer. Further analysis 
encompassing this gene might provide deeper insight towards understanding breast cancer 
aetiology and give clue towards manipulating the associated pathways for cure of this 
disease. LAMB1 expression was up-regulated in case of breast cancer as compared to normal 
breast sample and further study may hint towards understanding mechanism metastasis in 
breast cancer. 
  
Future scope 
Future studies on genes out of 255 differentially expressed genes which are yet not been 
validated in breast cancer, but are expressed in breast cancer will provide deeper insight into 
disease etiology of breast cancer. 
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